Trial · NCT03694002
Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
NCT03694002, Phase 2, Completed, SWOG Cancer Research Network; results first posted 2025-10-30
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery. Trials, record NCT03694002. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03694002
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
- NCT number
- NCT03694002
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 21 participants, actual
- Lead sponsor
- SWOG Cancer Research Network
- Conditions
- Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma, Recurrent Thymic Carcinoma, Unresectable Thymic Carcinoma
- Interventions
- Carboplatin, Paclitaxel, Ramucirumab
- First posted
- 2018-10-03
- Last updated
- 2025-10-30
- Results first posted
- 2025-10-30
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival | up to 2 years after registration | Compare progression-free survival between patients with incurable unresectable locally advanced, or recurrent, or metastatic thymic carcinoma randomized to carboplatin-paclitaxel with or without ramucirumab. Progression-free survival is defined as: From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Progression is defined as: 20% increase in the sum of appropriate diameters of target measurable lesions over smallest sum observed, as well as an absolute increase of at least 0.5 cm. Unequivocal progression of non-measurable disease in the opinion of the treating physician (an explanation must be provided). Appearance of any new lesion/site. Death due to disease without prior documentation of progression and without symptomatic deterioration |
| Secondary | Frequency and Severity of Adverse Events | Up to 2 years post randomization | Only adverse events that are possibly, probably or definitely related to study drug are reported. |
| Secondary | Response Rate | Up to 2 years after registration | To compare the response rate (complete response, partial response, confirmed and unconfirmed) between treatment arms in the subset of this patient population with measurable disease. Complete response - Complete disappearance of all target and non-target lesions (with the exception of lymph nodes mentioned below). No new lesions. No disease related symptoms. Any lymph nodes (whether target or non-target) must have reduction in short axis to \< 1.0 cm. Partial response - Applies only to patients with at least 1 measurable lesion. Greater than or equal to 30% decrease under baseline of the sum of appropriate diameters of all targets measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. |
| Secondary | Disease Control Rate | Up to 2 years after registration | To compare disease control rate (complete response, partial response, confirmed or unconfirmed, stable disease) between treatment arms in the subset of this patient population with measurable disease. |
| Secondary | Overall Survival | Up to 2 years after registration | To compare overall survival between treatment arms. Overall survival is defined as time from date of registration to date of death due to any cause. Because of low accrual, and too few participant deaths, we do not plan to analyze or report with outcome. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival | up to 2 years after registration | All eligible participants who received at least one cycle of treatment. | Months | MEDIAN |
| SECONDARY | Frequency and Severity of Adverse Events | Up to 2 years post randomization | Participants who received any protocol treatment | Participants | NUMBER |
| SECONDARY | Response Rate | Up to 2 years after registration | Participants who had measurable disease. 2 participants in the active comparator arm did not have measurable disease. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Disease Control Rate | Up to 2 years after registration | Participants with measurable disease and achieved a response. 2 participants in the active comparator arm had non-measurable disease. 6 participants in the active comparator arm had no response and 1 participants in the experimental arm had no response. | months | MEDIAN |
| SECONDARY | Overall Survival | Up to 2 years after registration | Only one death has been reported - so this outcome can not be completed. | months | MEDIAN |
Source ClinicalTrials.gov
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | 8 | 80% Confidence Interval 7 to 11 | Months | |
| Progression-free Survival | Active Comparator: Arm B (Carboplatin, Paclitaxel) | 7 | 80% Confidence Interval 6 to 8 | Months | |
| Frequency and Severity of Adverse Events | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | Anemia | 1 | Participants | |
| Frequency and Severity of Adverse Events | Active Comparator: Arm B (Carboplatin, Paclitaxel) | Anemia | 0 | Participants | |
| Frequency and Severity of Adverse Events | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | Diarrhea | 1 | Participants | |
| Frequency and Severity of Adverse Events | Active Comparator: Arm B (Carboplatin, Paclitaxel) | Diarrhea | 0 | Participants | |
| Frequency and Severity of Adverse Events | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | Dyspnea | 1 | Participants | |
| Frequency and Severity of Adverse Events | Active Comparator: Arm B (Carboplatin, Paclitaxel) | Dyspnea | 0 | Participants | |
| Frequency and Severity of Adverse Events | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | Ejection fraction decreased | 1 | Participants | |
| Frequency and Severity of Adverse Events | Active Comparator: Arm B (Carboplatin, Paclitaxel) | Ejection fraction decreased | 0 | Participants |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | 8 | |
| Overall Study | STARTED | Active Comparator: Arm B (Carboplatin, Paclitaxel) | 13 | |
| Overall Study | COMPLETED | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | 1 | |
| Overall Study | COMPLETED | Active Comparator: Arm B (Carboplatin, Paclitaxel) | 7 | |
| Overall Study | NOT COMPLETED | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | 7 | |
| Overall Study | NOT COMPLETED | Active Comparator: Arm B (Carboplatin, Paclitaxel) | 6 |
Source ClinicalTrials.gov
Adverse events160
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | 2 | 8 | |
| other | Anemia | Blood and lymphatic system disorders | Active Comparator: Arm B (Carboplatin, Paclitaxel) | 1 | 9 | |
| other | Cardiac disorders-Other | Cardiac disorders | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | 1 | 8 | |
| other | Cardiac disorders-Other | Cardiac disorders | Active Comparator: Arm B (Carboplatin, Paclitaxel) | 1 | 9 | |
| other | Palpitations | Cardiac disorders | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | 1 | 8 | |
| other | Palpitations | Cardiac disorders | Active Comparator: Arm B (Carboplatin, Paclitaxel) | 0 | 9 | |
| other | Sinus tachycardia | Cardiac disorders | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | 0 | 8 | |
| other | Sinus tachycardia | Cardiac disorders | Active Comparator: Arm B (Carboplatin, Paclitaxel) | 1 | 9 | |
| other | Hypothyroidism | Endocrine disorders | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | 1 | 8 | |
| other | Hypothyroidism | Endocrine disorders | Active Comparator: Arm B (Carboplatin, Paclitaxel) | 0 | 9 |
1 to 10 of 160Source ClinicalTrials.gov
See all 160 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | 1 | 8 |
| Total, all-cause mortality | Active Comparator: Arm B (Carboplatin, Paclitaxel) | 2 | 9 |
| Total, other adverse events | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | 8 | 8 |
| Total, other adverse events | Active Comparator: Arm B (Carboplatin, Paclitaxel) | 9 | 9 |
| Total, serious adverse events | Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) | 3 | 8 |
| Total, serious adverse events | Active Comparator: Arm B (Carboplatin, Paclitaxel) | 0 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10CA180888 | SWOG Network Group Operations Center of the NCTN | LARA, PRIMO N.; HERSHMAN, DAWN | UNIVERSITY OF CALIFORNIA AT DAVIS | NATIONAL CANCER INSTITUTE | 2014 to 2026 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) vs Active Comparator: Arm B (Carboplatin, Paclitaxel): deaths from any cause | Trial comparisons |
| Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) vs Active Comparator: Arm B (Carboplatin, Paclitaxel): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03694002
GET https://conductscience.org/api/trials/v1/NCT03694002/results?page=2